Naab Al‐Saady

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Andreas Goette, José Luís Merino, Michael D. Ezekowitz et al. · The Lancet · 2016 · 243 citations

Thrombosis, Cardiovascular Disease, Pharmacology +8

Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion

Mark M. Gallagher, Brian J. Hennessy, Nils Edvardsson et al. · Journal of the American College of Cardiology · 2002 · 172 citations

Cardiogenic Shock, Cardiac Anaesthesia, Embolic Complications +13

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

John J.P. Kastelein, Joost Besseling, Sukrut Shah et al. · The Lancet · 2015 · 99 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +7

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

B. Alexander Yi, Debra Freedholm, Nancy Widener et al. · Journal of Thrombosis and Haemostasis · 2021 · 92 citations · Full text

Advantages of a narrow-range, medium molecular weight hydroxyethyl starch for volume maintenance in a porcine model of fecal peritonitis

Andrew Webb, D. Tighe, RAY F. MOSS et al. · Critical Care Medicine · 1991 · 64 citations